PMC:7048180 / 873-1091
Annnotations
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":21,"end":23},"obj":"Chemical"},{"id":"T5","span":{"begin":40,"end":47},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_73601"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_53000"}],"text":" with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeu"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":36,"end":123},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeu"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":84,"end":88},"obj":"Gene"},{"id":"45","span":{"begin":6,"end":15},"obj":"Species"},{"id":"46","span":{"begin":109,"end":118},"obj":"Species"},{"id":"56","span":{"begin":51,"end":57},"obj":"Chemical"},{"id":"57","span":{"begin":151,"end":157},"obj":"Chemical"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Gene:59272"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:2697049"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeu"}